DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: SOF/VEL

First Posted Date: 2015-06-24

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 107

Registration Number: NCT02480712

Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

Phase 4

Terminated

Conditions: Hepatitis B

Interventions: Drug: Tenofovir DF
Radiation: DEXA Scan

First Posted Date: 2015-06-24

Last Posted Date: 2019-05-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 30

Registration Number: NCT02479880

Locations: 🇬🇷
Attikon General Hospital Of Athens, Chaidari, Greece
🇫🇷
Hopital Femmes Meres Enfants, Bron, France
🇮🇹
Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

and more 8 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection

Phase 3

Completed

Conditions: Hepatitis C Virus Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2015-06-16

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 153

Registration Number: NCT02472886

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

Phase 3

Completed

Conditions: HIV-1 Infection

Interventions: Drug: F/TAF
Drug: ABC/3TC
Drug: ABC/3TC Placebo
Drug: F/TAF Placebo
Drug: 3rd ARV agent

First Posted Date: 2015-06-11

Last Posted Date: 2019-10-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 567

Registration Number: NCT02469246

Locations: 🇺🇸
Pacific Oaks Medical Group, Beverly Hills, California, United States
🇺🇸
Anthony Mills, MD, Inc., Los Angeles, California, United States
🇺🇸
Peter J. Ruane, MD, Inc., Los Angeles, California, United States

and more 77 locations

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Terminated

Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma
Relapsed/Refractory Pancreatic Ductal Adenocarcinoma

Interventions: Drug: Idelalisib
Drug: Nab-paclitaxel
Drug: mFOLFOX6

First Posted Date: 2015-06-11

Last Posted Date: 2021-04-02

Lead Sponsor: Gilead Sciences

Target Recruit Count: 16

Registration Number: NCT02468557

Locations: 🇺🇸
Dana Farber/ Harvard Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Greenville Hospital System, Greenville, South Carolina, United States
🇺🇸
Indiana University Goshen Center for Cancer Care, Goshen, Indiana, United States

and more 6 locations

Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3

Phase 2

Completed

Conditions: Non-Alcoholic Steatohepatitis (NASH)

Interventions: Drug: SEL
Biological: SIM

First Posted Date: 2015-06-09

Last Posted Date: 2019-06-26

Lead Sponsor: Gilead Sciences

Target Recruit Count: 72

Registration Number: NCT02466516

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 25 locations

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection

Phase 2

Completed

Conditions: Hepatitis C Infection With HIV Co-Infection

Interventions: Drug: LDV/SOF

First Posted Date: 2015-05-29

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 26

Registration Number: NCT02457611

Study to Assess the Long-term Safety and Efficacy of Tirabrutinib in Adults With Relapsed/Refractory B-cell Malignancies

Phase 1

Completed

Conditions: Relapsed/Refractory B-cell Malignancies

Interventions: Drug: Tirabrutinib

First Posted Date: 2015-05-29

Last Posted Date: 2022-03-24

Lead Sponsor: Gilead Sciences

Target Recruit Count: 29

Registration Number: NCT02457559

Locations: 🇫🇷
Hopital Saint Eloi, Montpellier, France
🇫🇷
Centre Hospitalier Lyon Sud, Pierre Benite, France
🇬🇧
Leicester Royal Infirmary, Leicester, United Kingdom

and more 3 locations

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Phase 1

Terminated

Conditions: B-cell Malignancies

Interventions: Drug: Tirabrutinib
Drug: Entospletinib
Drug: Idelalisib
Drug: Obinutuzumab

First Posted Date: 2015-05-29

Last Posted Date: 2024-10-11

Lead Sponsor: Gilead Sciences

Target Recruit Count: 203

Registration Number: NCT02457598

Locations: 🇬🇧
Cardiff and Vale Health Board, Clinical Research Facility, Cardiff, United Kingdom
🇺🇸
Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸
Georgetown University Medical Center, Washington, District of Columbia, United States

and more 12 locations

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

Phase 1

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Eleclazine

First Posted Date: 2015-05-12

Last Posted Date: 2015-12-22

Lead Sponsor: Gilead Sciences

Target Recruit Count: 55

Registration Number: NCT02441829

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy